Brian R. Mueller

Executive Vice President & Chief Financial Officer at BioMarin Pharmaceutical, Inc.

Brian R. Mueller

Brian R. Mueller

Executive Vice President & Chief Financial Officer at BioMarin Pharmaceutical, Inc.

Overview
Career Highlights

BioMarin Pharmaceutical, Inc.

RelSci Relationships

619

Number of Boards

1

Birthday

1974

Age

47

Contact Data
Trying to get in touch with Brian R. Mueller? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Brian R. Mueller likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Executive Vice President, General Counsel & Secretary at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Executive Chairman at LQT Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Rapidscan Pharma Solutions, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Neurana Pharmaceuticals, Inc.

Relationship likelihood: Strong

Senior Vice President, Chief Compliance Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Chief Information Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Chief Medical Officer & Executive Vice President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Group Vice President & Head-Global Regulatory Affairs at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Executive Vice President, Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Paths to Brian R. Mueller
Potential Connections via
Relationship Science
You
Brian R. Mueller
Executive Vice President & Chief Financial Officer at BioMarin Pharmaceutical, Inc.
Education
B.S. in Accountancy

Chartered in 1895, Northern Illinois University first opened its doors in 1899 as the Northern Illinois State Normal School solely to prepare college-educated teachers. The university has since grown into a world-class university that attracts students from around the globe while still serving the northern Illinois region. We remain deeply committed to preparing teachers and providing an excellent and affordable higher education to Illinois families.

Memberships
Member
Current

The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY.

Career History
Executive Vice President & Chief Financial Officer
2002 - Current

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Senior Manager
2002 - Prior

KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY.

Vice President
Prior

Professional Control Corp. provides industrial automation and control distributor services. Its services include design and engineering through installation, testing and training for industrial automation systems. The company provides software based productivity solutions for warehousing and order fulfillment companies. Professional Control was founded in 1980 and headquartered in Germantown, WI

Public Holdings
Restricted data only for RelSci Enterprise users.
Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Brian R. Mueller. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Brian R. Mueller's profile does not indicate a business or promotional relationship of any kind between RelSci and Brian R. Mueller.